Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
It was recently reported that tyrosine kinase inhibitor imatinib mesylate (Gleevec®) improves Type 2 diabetes, possibly by decreasing insulin resistance. However, as both Type 2 and Type 1 diabetes are characterized by β‐cell dysfunction and death, we investigated whether imatinib counteracts diabetes by maintaining β‐cell function. We observed that imatinib counteracted diabetes in two animal models, the streptozotocin‐injected mouse and the nonobese diabetes mouse, and that this was paralleled by a partial preservation of the β‐cell mass. In addition, imatinib decreased the death of human β‐cells in vitro when exposed to NO, cytokines, and streptozotocin. The imatinib effect was mimicked by siRNA‐mediated knockdown of c‐Abl mRNA. Imatinib enhanced β‐cell survival by promoting a state similar to ischemic preconditioning, as evidenced by NF‐B activation, increased NO and reactive oxygen species production, and depolarization of the inner mitochondrial membrane. Imatinib did not suppress islet cell death in the presence of an NF‐B inhibitor, suggesting that NF‐B activation is a necessary step in the antiapoptotic action of imatinib. We conclude that imatinib mediates β‐cell survival and that this could contribute to the beneficial effects observed in diabetes.—Hägerkvist, R., Sandler, S., Mokhtari, D., Welsh, N. Amelioration of diabetes by imatinib mesylate (Gleevec®): role of β‐cell NF‐B activation and anti‐apoptotic preconditioning. FASEB J. 21, 618–628 (2007)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Preconditioning the myocardium: from cellular physiology to clinical cardiology
YELLON, D. M., & DOWNEY, J. M. (2003) · Physiological Reviews · doi:10.1152/physrev.00009.2003 · Cited by 1,062
The NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588 · cited 1×
“The NOD mouse is a genetic model for Type 1 diabetes in which -cells are destroyed by islet-infiltrating immune cells (14).”
BackgroundAn immune origin of type 2 diabetes?
Kolb, H., & Mandrup-Poulsen, T. (2005) · Diabetologia · doi:10.1007/s00125-005-1764-9 · Cited by 394 · cited 2×
“Considering the proapoptotic actions of active c-Abl and that both noninsulin dependent (Type 2) and insulin-dependent (Type 1) diabetes mellitus are characterized by an augmented destruction of insulin-producing -cells (12, 13), we investigated whether two unrelated animal models for diabetes and -cell destruction, t…”
Background
Cited by
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0355-7 · Cited by 854
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
“These effects are thought to be due to a combination of anti-inflammatory effects short term, due at least in part to its PDGFR antagonism, combined with longer term effects, perhaps due to its c-abl- and c-kit-specific activities (Hagerkvist et al., 2007).”
BackgroundBreccia, M., Molica, M., & Alimena, G. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.016 · Cited by 54
Metadata
- Authors
- Hägerkvist, R., Sandler, S., Mokhtari, D., & Welsh, N.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-11-29
- Volume
- 21
- Issue
- 2
- Pages
- 618-628
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1993124906
- Cited by
- 132
- References
- 4
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning. https://app.cochat.ai/papers/10.1096/fj.06-6910com
- The paper
- Hägerkvist, R., Sandler, S., Mokhtari, D., & Welsh, N. (2007). Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning. The FASEB Journal. https://doi.org/10.1096/fj.06-6910com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.